Tesamorelin + Ipamorelin
A research stack combining tesamorelin (an FDA-approved GHRH analog for HIV-associated visceral fat) with ipamorelin, aimed at fat loss and growth-hormone support. No human trials exist on the combination itself.
In plain English
This blend pairs tesamorelin — a GHRH analog that is FDA-approved specifically to reduce excess belly fat in people with HIV-associated lipodystrophy — with ipamorelin, a selective GH secretagogue. The idea is to combine a GHRH-pathway agent with a ghrelin-pathway agent for stronger, more pulsatile GH release and fat-loss support. Tesamorelin on its own has solid human trial evidence for its one approved use. But there are no studies of this specific combination, and using tesamorelin off-label or stacked is not supported by trial data. Ipamorelin is not FDA-approved at all.
What it is
A combination of tesamorelin — a stabilized analog of growth-hormone-releasing hormone (GHRH), FDA-approved as Egrifta for HIV-associated lipodystrophy — and ipamorelin, an unapproved selective ghrelin/GHS-receptor secretagogue research peptide.
Mechanism (summary)
Tesamorelin stimulates the GHRH receptor to increase endogenous GH and IGF-1, with a well-documented effect of reducing visceral adipose tissue. Ipamorelin acts at the separate GHS-R (ghrelin) receptor and reduces somatostatin tone. Stacking a GHRH analog with a secretagogue is intended to drive a larger, more physiologic GH pulse than either alone. This combined mechanism is inferred from the single agents and has not been tested in controlled human combination studies.
Why people research it
- Visceral (abdominal) fat reduction
- Growth-hormone and IGF-1 support for body composition
- Whether dual-pathway stimulation enhances fat-loss effects
- Metabolic and recovery applications
Human evidence
No published human trials test the tesamorelin + ipamorelin combination. Tesamorelin alone has strong, FDA-reviewed RCT evidence for reducing visceral fat in HIV-associated lipodystrophy and has been studied for liver fat and cognition. Ipamorelin alone has only limited human data. Combining the two is an off-label extrapolation: the visceral-fat evidence belongs to tesamorelin monotherapy in a specific patient population, not to this stack in healthy users.
Animal / lab evidence
Ipamorelin's selective GH-releasing profile was established in animal models. GHRH analogs raise GH in animals as well. There is no meaningful animal literature on this particular blend; its rationale rests on the components' individual pharmacology.
Key studies
Each summary explains the design, what was found, and what it doesn't prove.
This supports the tesamorelin half of the blend: it reliably cut belly and liver fat in HIV patients. It does not test the combination or apply to general fat loss.
Component evidence for the ipamorelin half — tested in surgery recovery, not fat loss, and not alongside tesamorelin.
History
Tesamorelin was developed by Theratechnologies and approved in 2010 for HIV lipodystrophy. Its pairing with ipamorelin originates in peptide-clinic practice, which layered a ghrelin-mimetic onto the GHRH analog to push fat-loss and GH effects beyond the approved indication.
PeptidePedia is for educational and informational purposes only. We do not sell peptides, prescribe peptides, provide medical advice, or recommend treatment. Peptides may not be approved for human use except in specific legal prescription or clinical contexts. Always consult a licensed medical professional before making health decisions.
Related peptides
A long-acting GHRH analog FDA-approved as Egrifta for HIV-associated visceral fat accumulation.
A selective ghrelin receptor agonist studied as a growth hormone secretagogue with minimal effects on cortisol or prolactin.
A long-acting GHRH analog studied as a research peptide for sustained growth hormone elevation.